Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged ≥12 years and older inclusive of either sex.~2. Documented clinical history of PAR (for at least 2 years preceding the Screening Visit \[Visit 1\]) and exhibiting a documented positive skin prick test (wheal diameter at least 3 mm greater than negative diluent control wheal) to at least 1 allergen known to induce PAR. Documentation of a positive result within 12 months prior to the Screening Visit (Visit 1) is acceptable.~Exclusion Criteria:~1. Pregnant or lactating women.~2. History of anaphylaxis and/or other severe local reaction(s) to skin testing.~3. History of positive test for HIV, Hepatitis B or Hepatitis C infection.~4. Documented evidence of acute or significant chronic sinusitis or chronic purulent postnasal drip.~5. Subjects with an active pulmonary disorder or infection.~6. Subjects with posterior subcapsular cataracts or glaucoma

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSP 301 NS (Type: EXPERIMENTAL): None
- GSP 301 Placebo NS pH 3.7 (Type: PLACEBO_COMPARATOR): None
- GSP 301 Placebo NS pH 7.0 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).